The Data Company Newswire (Page 5)

The Data Company Newswire (Page 5)

Comprehensive Real-Time News Feed for The Data Company. (Page 5)

Results 81 - 100 of 19,076 in The Data Company

  1. Safety concerns inspire more black women in Chicago to become concealed carry gun ownersRead the original story w/Photo

    Tuesday Sep 12 | Chicago Tribune

    Vernetta Robinzine recently became a concealed carry gun owner out of concerns for increasing crime in her area. Vernetta Robinzine recently became a concealed carry gun owner out of concerns for increasing crime in her area.

    Comment?

  2. Aurigene Discovery Technologies Limited, A Wholly Owned Subsidiary Of ...Read the original story

    Monday Sep 11 | BioSpace

    Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. and a specialized biotechnology company engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases, today announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.

    Comment?

  3. Equifax leaves Canadian and British hack victims in the darkRead the original story w/Photo

    Tuesday Sep 12 | CNN

    The credit reporting company said in a statement last Thursday that there had been "unauthorized access to limited personal information for certain U.K. and Canadian residents." Americans have been able to log onto the company's website and input information that will help determine if they've fallen victim to the hackers.

    Comment?

  4. Open-Silicon Completes Successful Silicon Validation of High...Read the original story w/Photo

    Tuesday Sep 12 | Design And Reuse

    Silicon validation in TSMC's 16nm FinFET technology and interoperability with HBM2 memory; Silicon-proven SoC solution enables next generation high bandwidth applications MILPITAS, CA– September 12, 2017 – Open-Silicon, a system-optimized ASIC solution provider, today announced it has successfully completed silicon validation of its High Bandwidth Memory IP subsystem in TSMC's 16nm FinFET technology in combination with TSMC's CoWoS® 2.5D silicon interposer technology and HBM2 memory. This full IP subsystem solution includes an HBM2 controller, PHY and interposer I/O, and completes the critical components needed for the successful integration of HBM2 memory into ASIC system-in-package designs.

    Comment?

  5. Clean vehicle sales skyrocket in ChinaRead the original story w/Photo

    Tuesday Sep 12 | UPI

    Sales of cleaner vehicles in the Chinese market increased more than 60 percent from last year as the world's second-largest economy greens up, data show. Data from the China Association of Automobile Manufacturers show total sales of 2.19 million vehicles last month marked a 5.3 percent increase from August 2016.

    Comment?

  6. Valmet Goes Digital with Dassault Syst mes to Improve Its Engineering and Sales for Paper & PulpRead the original story w/Photo

    Monday Sep 11 | Customer Interaction Solutions

    Dassault SystA mes is enabling Valmet , a leading developer and supplier of technologies, automation and services for the pulp, paper and energy industries, to increase customer satisfaction by proposing more innovative customer-oriented experiences at each service and sales opportunity. Valmet is using the " Single Source for Speed " industry solution experience to unify and manage its product development and order fulfillment across its engineering and service centers in 30 countries.

    Comment?

  7. GlaxoSmithKline Eyes the Line at the Fda With Mixed Phase III Copd DataRead the original story

    Monday Sep 11 | BioSpace

    GSK Announces Phase III Results Published In NEJM Of Mepolizumab In Patients With Eosinophilic COPD At Risk Of Exacerbations - Regulatory filings planned for 2017 GlaxoSmithKline plc today announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease . Data from the investigational clinical development programme showed that treating eosinophilic COPD patients with the biologic medicine, mepolizumab, in addition to maximal guideline-recommended therapy, reduced exacerbations in these difficult-to-treat patients.

    Comment?

  8. Nativis, Inc. Announces Expanded Clinical Program In Glioblastoma MultiformeRead the original story

    Monday Sep 11 | BioSpace

    Nativis, Inc. , a clinical stage life science bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced expansion of its clinical program in Glioblastoma Multiforme . Chris Rivera, Nativis President and Chief Executive Officer, announced that based on encouraging safety and survival data, the current feasibility study in recurrent GBM, NAT-101, will be expanded to enroll up to 32 more patients in the combination therapy arm - i.e., Nativis VoyagerA plus a standard chemotherapy drug.

    Comment?

  9. Economic growth, reg relief, tax reform headline NAFCU's CaucusRead the original story

    Monday Sep 11 | NAFCU

    Mark Calabria, chief economist for Vice President Mike Pence, spoke to hundreds of Congressional Caucus attendees Monday about the administration's new directions in economic policy and specifically discussed economic growth. In addition to Calabria, Caucus attendees Monday heard from three members of the House Financial Services Committee on issues affecting the credit union industry, including regulatory relief, tax reform and preservation of credit unions' federal tax exemption.

    Comment?

  10. National debt hits $20 trillion for first time in historyRead the original story w/Photo

    Monday Sep 11 | Washington Examiner

    The national debt exceeded $20 trillion for the first time ever on Friday, the same day President Trump signed a bill into law that suspended the debt ceiling and allowed unlimited federal borrowing. The debt ceiling had been frozen at about $19.84 trillion since mid-March, and the Treasury Department was forced to use "extraordinary measures" to prevent borrowing from exceeding that level.

    Comment?

  11. Catalyst Biosciences Announces Issuance Of Asia Patents Covering Factor IX Hemophilia ProgramRead the original story

    Sunday Sep 10 | BioSpace

    Catalyst Biosciences, Inc. , today announced that it has been issued patents covering its coagulation Factor IX hemophilia product candidate from the State Intellectual Property Office in the People's Republic of China, the Intellectual Property Office of Singapore , and the Taiwan Intellectual Property Office . The patents cover both modified Factor IX polypeptides and uses thereof, and build on the Company's extensive intellectual property portfolio.

    Comment?

  12. Boehringer Ingelheim Release: Safety And Efficacy Results From The...Read the original story

    Sunday Sep 10 | BioSpace

    Data from this 12-week study show that the safety and tolerability profile of nintedanib with add-on pirfenidone is in keeping with the known profiles of the individual drugs in patients with IPF1 Results from INJOURNEYTM add to the body of evidence from a comprehensive clinical trial programme substantiating nintedanib's safety and efficacy in IPF INGELHEIM, Germany-- --Results from the INJOURNEYTM trial, investigating the use of nintedanib in combination with pirfenidone in treating idiopathic pulmonary fibrosis , have just been published in the American Journal of Respiratory and Critical Care Medicine.

    Comment?

  13. ImmusanT, Inc. Presents Data From Multiple Studies Supporting Continued Development Of Nexvax2Read the original story

    Sunday Sep 10 | BioSpace

    ImmusanT, Inc. , a clinical-stage company developing Nexvax2A , a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced it has presented data demonstrating the immunologic basis for the early clinical effects of gluten in celiac disease. The results were presented in two poster presentations and summarized in an invited oral presentation at the International Celiac Disease Symposium , which occurred September 8-10, 2017 in New Delhi, India.

    Comment?

  14. Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data...Read the original story w/Photo

    Monday Sep 11 | GlobeNewswire

    Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Hakko Kirin Co., Ltd. today announced positive data from two ongoing Phase 2 studies - 40 week data from the study in children less than five years old with X-linked hypophosphatemia and 24 week data from the study in adult tumor-induced osteomalacia patients.

    Comment?

  15. Bureaucracy Power Grab Comment Periods Are Always Stupid - and Often CorruptRead the original story w/Photo

    Monday Sep 11 | RedState

    We have very many times discussed the very many unilateral power grabs of the very many Executive Branch departments, agencies, commissions and boards. And we have noted that a particularly stupid part of these power grab processes - is the fake democracy veneer applied that is the Comment Period : "Where some agency of which you've never heard - and to whom you've elected no one - quietly announces a period where you can file thoughts on the damage they're about to inflict upon you.

    Comment?

  16. Tucatinib Data in Multiple Tumor Types Presented at the European...Read the original story

    Monday Sep 11 | Customer Interaction Solutions

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced tucatinib data in multiple tumor types were presented at the European Society for Medical Oncology 2017 Congress being held September 8-12, 2017 in Madrid, Spain. Results from the pooled analysis of Phase 1b combination studies support the potential utility of tucatinib for patients with HER2-positive metastatic breast cancer with brain metastases, including untreated or progressive brain metastases after radiation therapy.

    Comment?

  17. Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017Read the original story w/Photo

    Monday Sep 11 | GlobeNewswire

    Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today presented preliminary data from the initial 34 patients with cancer treated in the dose escalation stage of the Phase 1 trial of CA-170 conducted in the U.S., South Korea and Spain, at the European Society for Medical Oncology 2017 Congress.

    Comment?

  18. Editorial: Kris Kobach and His 5,313 Fraudulent VotersRead the original story w/Photo

    Sunday Sep 10 | The New York Times

    The voter-fraud crusaders who run President Trump's electoral-integrity commission have found their holy grail: evidence that large-scale illegal voting swung a pivotal Senate election in 2016. In his latest column for Breitbart News , Kris Kobach, the commission's vice chairman, called it "highly likely" that the election of Maggie Hassan, New Hampshire's Democratic candidate for the Senate, was "stolen through voter fraud."

    Comment?

  19. Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma TrialRead the original story w/Photo

    Sunday Sep 10 | PR-inside.com

    September 11, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints. Dupilumab, when added to standard therapies, reduced severe asthma attacks and improved lung function.

    Comment?

  20. Teva Showcases Data Demonstrating Potential Of Fremanezumab To...Read the original story

    Sunday Sep 10 | BioSpace

    Teva Pharmaceutical Industries Ltd., has presented new data evaluating fremanezumab, an investigational treatment for the prevention of migraine, at the 18th Congress of the International Headache Society in Vancouver, Canada. Data presented across two platform presentations and five late-breaking abstracts featured detailed, positive efficacy results from pivotal Phase III HALO studies of fremanezumab in chronic and episodic migraine , as well as data from patient-reported outcomes tools in the chronic migraine trial.

    Comment?